Testing PreCursor-M+® for CIN2 management
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new tool called PreCursor-M+® to see how well it helps doctors manage CIN2, a moderate cervical cell change. It’s for people who have already been diagnosed with CIN2 and know their HPV test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with CIN2 (a moderate abnormal cell change in the cervix) after a biopsy or a treatment like a LEEP or laser conization.
- You know the results of your HPV test.
- You can understand and sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tissue samples from cervical biopsies to find markers that might help predict whether precancerous changes could become cancer. It may help doctors better understand and manage cervical precancer.
This trial checks whether “therapy abstention” (not treating right away) and close monitoring is safe for certain high-grade cervical cell changes. It may help some people avoid immediate procedures while still catching any progression early.
This trial tests a light-activated therapy (called HAL-PDT) for a specific type of abnormal cervical cell change known as CIN2. It aims to see if this treatment can destroy the abnormal cells while keeping the cervix healthy, potentially avoiding surgery.
This study tests a new questionnaire that may help doctors better identify which women need treatment for cervical changes. It is for women who have had an abnormal Pap smear or a positive HPV test and are going for a colposcopy (a closer look at the cervix).
This study tests whether honey applied directly to the cervix can help reverse moderate cervical cell changes (CIN II). It may offer a natural alternative to more invasive procedures.
This trial compares a liquid-based cytology test with a molecular screening test to find early changes in the cervix that could lead to cancer. It may help you understand which test is better at detecting these changes before they become serious.
Hear when a new Cervical Intraepithelial Neoplasia Grade 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.